Vomiting: Drugs That Cause It and Drugs That Treat It

How the Vomiting Reflex Works and Why Drugs Affect It

Vomiting is a coordinated reflex controlled by two brain regions: the chemoreceptor trigger zone (CTZ) in the area postrema and the nucleus tractus solitarius in the medulla. These regions receive input from the gastrointestinal tract, vestibular system, and higher cortical centers. Any drug that stimulates receptors in these pathways can provoke emesis.

The CTZ sits outside the blood-brain barrier, which means circulating drugs and toxins reach it directly 1. This anatomical detail explains why so many systemically administered medications cause vomiting. Four receptor types do most of the work: serotonin 5-HT3, dopamine D2, neurokinin NK1, and histamine H1. Chemotherapy drugs, for instance, trigger massive serotonin release from enterochromaffin cells in the gut lining. That serotonin surge activates vagal afferents and the CTZ simultaneously 2.

Short version: vomiting is not one pathway. It is several overlapping circuits, and different drugs hijack different entry points. A medication that acts on dopamine receptors (like metoclopramide) will not help much if the vomiting is driven primarily by serotonin release. This is why identifying the cause matters before choosing an antiemetic.

Drugs That Commonly Cause Vomiting

The list of emetogenic medications is long, but a few drug classes account for most clinical encounters. Understanding which drugs carry the highest risk helps clinicians anticipate problems and prescribe prophylactic antiemetics when appropriate.

Chemotherapy agents are the most studied offenders. The Hesketh emetogenicity classification groups chemotherapy drugs into four tiers 3. High-emetic-risk agents include cisplatin, dacarbazine, and the combination of anthracycline plus cyclophosphamide. Without antiemetic prophylaxis, cisplatin causes vomiting in more than 90% of patients. The American Society of Clinical Oncology (ASCO) antiemetic guidelines, updated in 2025, recommend triple-drug prophylaxis with a 5-HT3 antagonist, dexamethasone, and an NK1 receptor antagonist for high-risk regimens 4.

Opioids cause nausea and vomiting in 25-40% of opioid-naive patients, according to a systematic review published in the Journal of Pain and Symptom Management 5. Opioids act directly on the CTZ through mu-receptor activation and also slow gastric motility, which compounds the problem. Morphine and codeine tend to produce more nausea than fentanyl patches, though individual variation is wide.

SSRIs and SNRIs cause nausea in 20-35% of patients during the first two weeks of therapy, making it one of the most common reasons for early discontinuation 6. The mechanism involves serotonin stimulation of 5-HT3 receptors in the gut. This side effect typically fades after 7-14 days, which is why clinicians often advise patients to take these medications with food and wait out the adjustment period.

Other notable emetogenic drug classes include:

• Antibiotics, especially erythromycin and metronidazole, which stimulate motilin receptors and directly irritate gastric mucosa
• NSAIDs, which damage the gastric lining through COX-1 inhibition, particularly at higher doses or with prolonged use
• Dopamine agonists like levodopa and bromocriptine, which stimulate D2 receptors in the CTZ
• Digoxin, where nausea and vomiting may signal toxicity at serum levels above 2.0 ng/mL 7

The Five Main Classes of Antiemetic Drugs

Antiemetics are grouped by their receptor targets. Each class works best against specific causes of vomiting, and combining agents from different classes often produces additive benefit.

5-HT3 Receptor Antagonists

Ondansetron (Zofran), granisetron, and palonosetron block serotonin receptors on vagal afferents and in the CTZ. This class transformed chemotherapy supportive care after ondansetron's approval in 1991. A landmark trial by Hesketh and colleagues demonstrated that ondansetron controlled acute chemotherapy-induced vomiting in 58-73% of patients receiving cisplatin, compared to 33% with metoclopramide 8. Palonosetron has a longer half-life of approximately 40 hours, which gives it an advantage for delayed-phase emesis 9.

Outside oncology, ondansetron is the go-to antiemetic in emergency departments for acute gastroenteritis. A 2012 Cochrane review of 10 trials (N=1,479 children) found that a single oral dose of ondansetron reduced immediate vomiting by 57% compared with placebo (RR 0.43 to 95% CI 0.33-0.56) 10. The drug is generally well tolerated, though the FDA issued a safety communication in 2012 regarding QT prolongation at intravenous doses above 16 mg 11.

NK1 Receptor Antagonists

Aprepitant (Emend) and its intravenous prodrug fosaprepitant block substance P binding at NK1 receptors in the brainstem. This class is particularly effective against delayed chemotherapy-induced vomiting, the type occurring 24-120 hours after treatment. In a key Phase III trial (N=569), adding aprepitant to ondansetron plus dexamethasone raised the complete response rate (no vomiting, no rescue therapy) from 52.3% to 72.7% over the 5-day observation period 12.

Dr. Paul Hesketh, a lead author of the ASCO antiemetic guidelines, has stated: "The addition of NK1 receptor antagonists to 5-HT3-based regimens represented the most significant advance in CINV control in the past two decades" 4.

Dopamine D2 Receptor Antagonists

Metoclopramide and prochlorperazine block dopamine D2 receptors in the CTZ and, in the case of metoclopramide, also promote gastric emptying through peripheral prokinetic effects. Metoclopramide is effective for gastroparesis-related vomiting and mild chemotherapy-induced nausea. It carries an FDA black-box warning for tardive dyskinesia with chronic use exceeding 12 weeks 13.

Prochlorperazine (Compazine), a phenothiazine, remains a cost-effective option for acute nausea in the emergency department. It works. But its side-effect profile includes sedation, akathisia, and extrapyramidal symptoms, which limits its appeal for repeated dosing.

Corticosteroids

Dexamethasone is not typically classified as a "pure" antiemetic, yet it is included in nearly every guideline-recommended chemotherapy antiemetic regimen. The mechanism is not fully understood but may involve prostaglandin inhibition in the brainstem and reduced permeability of the blood-brain barrier to emetogenic substances 14. The Italian Group for Antiemetic Research showed that adding dexamethasone to a 5-HT3 antagonist improved complete protection from acute emesis from 60% to 78% 15.

Antihistamines and Anticholinergics

Dimenhydrinate (Dramamine), meclizine, and scopolamine target histamine H1 and muscarinic receptors, respectively. These agents work best for motion sickness and vestibular-mediated vomiting. Scopolamine transdermal patches deliver 1 mg over 72 hours and are recommended by the NCCN for motion sickness prophylaxis. They have minimal utility in chemotherapy-induced or drug-induced emesis 16.

Matching the Antiemetic to the Cause

The single biggest prescribing error in antiemetic therapy is using the wrong class for the wrong trigger. A practical approach:

Chemotherapy-induced vomiting (CINV): Follow ASCO/MASCC/NCCN guidelines, which stratify regimens by emetogenicity. High-risk protocols call for a three-drug combination: a 5-HT3 antagonist, dexamethasone, and an NK1 antagonist. The MASCC/ESMO 2016 guidelines added olanzapine 10 mg for highly emetogenic chemotherapy based on the Phase III trial by Navari and colleagues (N=380), which showed olanzapine raised the complete response rate in the delayed phase from 66% to 83% 17.

Opioid-induced nausea and vomiting (OINV): Start with a low-dose dopamine antagonist such as metoclopramide 10 mg three times daily or haloperidol 0.5-1 mg at bedtime. If the patient cannot tolerate dopamine antagonists, ondansetron 4-8 mg every 8 hours is a reasonable second line. Tolerance to opioid-induced nausea usually develops within 5-7 days 5.

Postoperative nausea and vomiting (PONV): The Apfel simplified risk score identifies four independent predictors: female sex, history of PONV or motion sickness, nonsmoking status, and postoperative opioid use 18. Patients with two or more risk factors receive combination prophylaxis. A 2020 consensus guideline recommends ondansetron 4 mg IV plus dexamethasone 4-8 mg IV as the baseline regimen, with droperidol or a scopolamine patch added for high-risk patients 19.

Gastroparesis-related vomiting: Metoclopramide remains the only FDA-approved prokinetic for gastroparesis. The recommended approach is the lowest effective dose for the shortest duration, ideally not exceeding 12 weeks, due to the tardive dyskinesia risk. Domperidone is available outside the U.S. and does not cross the blood-brain barrier as readily, reducing extrapyramidal risk 20.

Vestibular vomiting: Meclizine 25 mg every 6-8 hours or a scopolamine patch applied behind the ear. 5-HT3 antagonists have minimal benefit here because the vestibular pathway is primarily histaminergic and cholinergic.

When Vomiting Signals a Medical Emergency

Most drug-induced vomiting is self-limiting. Stop the offending agent, provide hydration, and the symptom resolves. Certain patterns demand immediate evaluation.

Vomiting blood (hematemesis) may indicate gastrointestinal bleeding from NSAID-induced ulceration or Mallory-Weiss tears from forceful retching. Bilious vomiting with abdominal distension suggests bowel obstruction. Projectile vomiting with a new headache raises concern for increased intracranial pressure. The American College of Emergency Physicians guidelines note that persistent vomiting with signs of dehydration (orthostatic hypotension, dry mucous membranes, reduced urine output) warrants intravenous fluid resuscitation and laboratory evaluation including electrolytes and renal function 21.

Dr. Mark Feldman, a gastroenterologist at UT Southwestern and co-editor of Sleisenger and Fordtran's Gastrointestinal and Liver Disease, has noted: "The critical distinction is between vomiting as a nuisance and vomiting as a harbinger. Metabolic alkalosis from prolonged emesis can itself become life-threatening if chloride and potassium are not repleted" 22.

Hypokalemia from repeated vomiting may cause cardiac arrhythmias. Serum potassium below 3.0 mEq/L requires monitoring and replacement. Severe dehydration with a serum bicarbonate above 30 mEq/L on a basic metabolic panel confirms significant chloride-responsive metabolic alkalosis.

Newer Antiemetic Approaches Under Investigation

Olanzapine, originally an atypical antipsychotic, has gained traction as a multipathway antiemetic because it blocks D2, 5-HT3, H1, and muscarinic receptors simultaneously. A reduced dose of 5 mg (instead of 10 mg) is now being studied to maintain efficacy while reducing sedation. Early results from a Japanese randomized trial (N=710) suggest the 5 mg dose achieves a comparable complete response rate of 78% versus 80% for the 10 mg dose in the delayed CINV phase, with significantly less somnolence (28% vs. 53%) 23.

Cannabinoid-based antiemetics, including dronabinol and nabilone, act on CB1 receptors in the dorsal vagal complex. A 2015 Cochrane review of 23 trials found cannabinoids were more effective than prochlorperazine for chemotherapy-induced nausea but caused more dizziness and dysphoria 24. These agents remain second- or third-line for patients who fail standard regimens.

NEPA (netupitant 300 mg/palonosetron 0.5 mg) combines an NK1 antagonist and a 5-HT3 antagonist in a single oral capsule, simplifying the prophylaxis regimen. The AVERT trial (N=1,455) demonstrated a complete response rate of 74.3% over the overall 120-hour phase with moderate-emetic-risk chemotherapy 25.

Practical Guidance for Patients Starting Emetogenic Medications

For anyone beginning a medication known to cause vomiting, several evidence-based steps reduce risk. Take the medication with food unless the label specifically directs otherwise. SSRIs and metformin both cause less nausea when taken after a meal. Start at the lowest available dose and titrate upward. For opioids, the initial 72 hours carry the highest nausea risk, so a short course of ondansetron 4 mg as needed during that window may prevent early discontinuation.

Stay upright for at least 30 minutes after taking oral medications. Ginger at doses of 1-1.5 g per day has shown modest antiemetic benefit in pregnancy-related nausea (a Cochrane review of 12 trials, N=1,278) and may help with mild drug-induced nausea, though evidence for chemotherapy-related use is mixed 26. Oral rehydration solutions containing glucose and electrolytes help offset fluid losses when vomiting occurs.

Report persistent vomiting lasting more than 24 hours to your prescribing clinician. If you cannot keep down oral medications or fluids, seek evaluation for intravenous hydration and possible antiemetic switching.